Jiangsu Bioperfectus Technologies Co., Ltd. (SHA:688399)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Diagnostic Reagent	313.53M	-						177.91M	122.46M
Diagnostic Reagent Growth	-	-						45.28%	-
Diagnostic Instruments	12.64M	-						6.41M	5.27M
Diagnostic Instruments Growth	-	-						21.57%	-
Testing Services	5.11M	-						96.25K	-
Other	81.21K	-						-	-
Software	-	-						45.30K	269.23K
Software Growth	-	-						-83.17%	-
Total	331.36M	-						184.47M	128.00M
Total Growth	-	-						44.11%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Foreign	12.77M	-
Northeast China	14.88M	-
North China	26.71M	-
East China	146.69M	-
South China	34.30M	-
Central China	37.01M	-
Northwest China	27.40M	-
Southwest China	31.59M	-
Hong Kong, Macau and Taiwan	2.54K	-
Total	331.36M	-

Source: S&P Global Market Intelligence.